Thomas Pålsson
Finanzdirektor/CFO bei CIRCHEM AB
Profil
Thomas Pålsson is currently the Chief Financial Officer at Toleranzia AB, Monivent AB, Stayble Therapeutics AB, CirChem AB, and is also the Owner & Procurator at Besattningen 1 Kommanditbolag.
He previously held the position of Chief Financial Officer at Arexis AB and Integrum AB.
Mr. Pålsson received a graduate degree and an MBA from Handelshögskolan i Göteborg.
Aktive Positionen von Thomas Pålsson
Unternehmen | Position | Beginn |
---|---|---|
CIRCHEM AB | Finanzdirektor/CFO | 01.09.2020 |
STAYBLE THERAPEUTICS AB | Finanzdirektor/CFO | 01.01.2018 |
MONIVENT AB | Finanzdirektor/CFO | - |
TOLERANZIA AB | Finanzdirektor/CFO | 30.10.2023 |
Fullriggaren Konsult AB | Finanzdirektor/CFO | - |
Besattningen 1 Kommanditbolag | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Thomas Pålsson
Unternehmen | Position | Ende |
---|---|---|
INTEGRUM AB | Finanzdirektor/CFO | 09.10.2019 |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Finanzdirektor/CFO | - |
Ausbildung von Thomas Pålsson
Handelshögskolan i Göteborg | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
INTEGRUM AB | Health Technology |
CIRCHEM AB | Process Industries |
STAYBLE THERAPEUTICS AB | Health Technology |
MONIVENT AB | Health Technology |
TOLERANZIA AB | Health Technology |
Private Unternehmen | 3 |
---|---|
Fullriggaren Konsult AB | |
Besattningen 1 Kommanditbolag | |
Arexis AB
Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Health Technology |